Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endophytic microorganisms as sustainable sources of antidiabetic metabolites: biochemical mechanisms, bioprospecting strategies, and translational challenges.

3 Biotech·2026
Same author

Normalized QRS Duration by LV Dimension: Eliminating Sex-Specific Differences and Predicting Cardiac Resynchronization Therapy Outcomes.

JACC. Clinical electrophysiology·2026
Same author

Author Correction: Folding-mediated secretion of pure bispecific antibodies.

Nature biotechnology·2025
Same author

Folding-mediated secretion of pure bispecific antibodies.

Nature biotechnology·2025
Same author

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins.

Scientific reports·2025
Same author

Multiplexed siRNA Immunoassay Unveils Spatial and Quantitative Dimensions of siRNA Function, Abundance, and Localization In Vitro and In Vivo.

Toxicologic pathology·2025

Related Experiment Video

Updated: Mar 13, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K

Engineering a targeted delivery platform using Centyrins.

Shalom D Goldberg1, Rosa M F Cardoso1, Tricia Lin1

  • 1Janssen Research and Development, L.L.C., 1400 McKean Road, Spring House, PA 19477, USA.

Protein Engineering, Design & Selection : PEDS
|October 15, 2016
PubMed
Summary
This summary is machine-generated.

Researchers engineered a Centyrin protein for targeted drug delivery. They identified 26 optimal sites for attaching drugs, enhancing delivery efficiency and potency for pharmaceutical development.

Keywords:
centyrin, cysteine scanning, EGFR, FN3 domain, targeted delivery

More Related Videos

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

13.4K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Related Experiment Videos

Last Updated: Mar 13, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K
Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

13.4K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Delivery Systems

Background:

  • Targeted delivery of therapeutics to specific cells is crucial for modern pharmaceuticals.
  • Antibody or scaffold proteins target cell-surface receptors for drug delivery.
  • Optimizing conjugation sites, linkers, and trafficking pathways impacts drug efficacy.

Purpose of the Study:

  • To engineer an Epidermal Growth Factor Receptor (EGFR) binding Centyrin for targeted drug delivery.
  • To systematically evaluate single-cysteine mutations for optimal conjugation and payload delivery.
  • To provide a structural basis for developing Centyrin-based drug delivery platforms.

Main Methods:

  • A comprehensive mutagenesis experiment was performed on an EGFR-binding Centyrin, a fibronectin type III (FN3) domain.
  • All possible single-cysteine replacements (94 positions) were assessed for expression, purification, and conjugation efficiency.
  • Target binding, biophysical properties, and cytotoxic payload delivery were evaluated for each variant.

Main Results:

  • 26 out of 94 evaluated positions were identified as ideal for cysteine modification and drug conjugation.
  • These optimal sites facilitated efficient conjugation and maintained target binding and payload delivery.
  • Conjugation-tolerant positions were mapped onto the Centyrin crystal structure.

Conclusions:

  • This study successfully identified optimal sites for engineering Centyrin-based targeted drug delivery systems.
  • The findings provide a structural and experimental foundation for developing novel Centyrin-targeted therapeutic platforms.
  • This approach enhances the efficiency and potency of small molecule drug delivery via specific protein targeting.